OLEMA PHARMACEUTICALS INC
OLMANASDAQTrading Snapshot
- Day Range
- $10.30 – $10.65
- 52-Week Range
- $4.47 – $36.26
- Volume
- $5.03B
- Avg Volume
- $5.64B
- Shares Outstanding
- 87.3M
- Next Earnings
- Sep 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $83M
- Last Q Revenue
- $21M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-2.03
- Dividend Yield
- —
Why Investors Own OLMA
- ✓High-growth profile — revenue up +11.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 56% gross margin and 19% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About OLEMA PHARMACEUTICALS INC
A company profile for OLEMA PHARMACEUTICALS INC isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $36
HC Wainwright & Co. analyst Emily Bodnar maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $38 to $36.
OppFi Posts Downbeat Q2 Earnings, Joins Upwork, Rocket Lab And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures mostly lower. OppFi (OPFI) shares fall after missing Q2 earnings and cutting FY26 guidance. Other stocks also down in pre-market.
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers P3 Health Partners (NASDAQ:PIII) shares increased by 24.1% to $15.92 during Monday's after-market session. The market value of their outstanding shares is at $38.5 million. As per the press release, Q2
Olema Pharmaceuticals Q2 EPS $(0.61) Misses $(0.55) Estimate
Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.55) by 10.91 percent. This is a 19.61 percent decrease over losses of $(0.51) per